02/14/2006

Delphi Partner Climbs The Midas List

David Douglass ranks as #16 top deal maker

Menlo Park - For the second consecutive year, Delphi Ventures General Partner David Douglass was named to the Forbes Midas List identifying the top 100 venture capital deal makers. David is among 15 healthcare investors to make this yearís list- a sign of the times that healthcare investing is on the rise. Despite market cycles, Delphi Ventures has remained committed to healthcare investing and has been the firmís sole focus since 1988.

Forbesí annual list recognizes individuals who deploy venture capital to create wealth for investors. This formula weighs most heavily the capitalization of a venture-backed company on its first day of trading or the purchase price in an acquisition. Companies must have gone public or been acquired after June 1995 and they must be in the field of information technology or life sciences. Placement also depends on investorís degree of involvement with a startup.

Davidís notable investments include Interventional Technologies, Inc.(Boston Scientific Corporation), ORATEC Interventions, Inc.(Smith & Nephew), TheraSense, Inc.(Abbott Laboratories, Inc.) and NeuroMetrix. Since 1979, David has been actively involved in managing and investing in over 50 high growth venture capital backed companies, primarily in the medical device industry. He joined Delphi Ventures in 1990.

"Our success is a tribute to David Douglass and the Partners at Delphi Ventures who led our Series A financing. David was instrumental in defining the strategic direction of our product development, recruiting senior management and supporting each additional financing. Delphi was a dedicated supporter of our company throughout our product launch and ultimate acquisition." Mark Lortz, President & CEO, TheraSense, Inc.

Delphi Ventures was founded in 1988 as a venture capital firm focused on early stage healthcare investing, including medical devices, diagnostics and biotechnology. More than 80 of Delphi backed companies have either completed an initial public offering or have been acquired by leading healthcare companies.